Skip to Content
Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2019
Odonate Therapeutics Announces Completion of Enrollment in CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer
